vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and Mistras Group, Inc. (MG). Click either name above to swap in a different company.
Mistras Group, Inc. is the larger business by last-quarter revenue ($181.5M vs $180.9M, roughly 1.0× AVANOS MEDICAL, INC.). Mistras Group, Inc. runs the higher net margin — 2.1% vs -0.7%, a 2.8% gap on every dollar of revenue. On growth, Mistras Group, Inc. posted the faster year-over-year revenue change (5.1% vs 0.7%). Mistras Group, Inc. produced more free cash flow last quarter ($26.0M vs $21.3M). Over the past eight quarters, AVANOS MEDICAL, INC.'s revenue compounded faster (4.4% CAGR vs -0.8%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
Mistras Group, Inc. is a global provider of asset integrity and protection solutions, offering non-destructive testing, inspection, real-time monitoring, and engineering consulting services. Its key client segments include oil and gas, aerospace, power generation, and manufacturing industries, with operations spanning North America, Europe, and Asia-Pacific, helping clients enhance operational safety, extend asset lifespans, and minimize unplanned downtime.
AVNS vs MG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $181.5M |
| Net Profit | $-1.3M | $3.8M |
| Gross Margin | 47.5% | 28.4% |
| Operating Margin | 1.4% | 7.0% |
| Net Margin | -0.7% | 2.1% |
| Revenue YoY | 0.7% | 5.1% |
| Net Profit YoY | 99.7% | -27.4% |
| EPS (diluted) | $-0.02 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $181.5M | ||
| Q3 25 | $177.8M | $195.5M | ||
| Q2 25 | $175.0M | $185.4M | ||
| Q1 25 | $167.5M | $161.6M | ||
| Q4 24 | $179.6M | $172.7M | ||
| Q3 24 | $170.4M | $182.7M | ||
| Q2 24 | $171.7M | $189.8M | ||
| Q1 24 | $166.1M | $184.4M |
| Q4 25 | $-1.3M | $3.8M | ||
| Q3 25 | $-1.4M | $13.1M | ||
| Q2 25 | $-76.8M | $3.0M | ||
| Q1 25 | $6.6M | $-3.2M | ||
| Q4 24 | $-397.3M | $5.2M | ||
| Q3 24 | $4.3M | $6.4M | ||
| Q2 24 | $1.8M | $6.4M | ||
| Q1 24 | $-900.0K | $995.0K |
| Q4 25 | 47.5% | 28.4% | ||
| Q3 25 | 48.4% | 29.8% | ||
| Q2 25 | 52.6% | 29.1% | ||
| Q1 25 | 53.6% | 25.3% | ||
| Q4 24 | 54.6% | 26.5% | ||
| Q3 24 | 54.5% | 26.8% | ||
| Q2 24 | 55.7% | 27.1% | ||
| Q1 24 | 57.1% | 25.0% |
| Q4 25 | 1.4% | 7.0% | ||
| Q3 25 | 0.1% | 10.4% | ||
| Q2 25 | -42.6% | 4.5% | ||
| Q1 25 | 6.1% | -0.6% | ||
| Q4 24 | -233.0% | 6.1% | ||
| Q3 24 | 7.0% | 6.5% | ||
| Q2 24 | 3.7% | 6.3% | ||
| Q1 24 | 2.4% | 3.0% |
| Q4 25 | -0.7% | 2.1% | ||
| Q3 25 | -0.8% | 6.7% | ||
| Q2 25 | -43.9% | 1.6% | ||
| Q1 25 | 3.9% | -2.0% | ||
| Q4 24 | -221.2% | 3.0% | ||
| Q3 24 | 2.5% | 3.5% | ||
| Q2 24 | 1.0% | 3.4% | ||
| Q1 24 | -0.5% | 0.5% |
| Q4 25 | $-0.02 | $0.12 | ||
| Q3 25 | $-0.03 | $0.41 | ||
| Q2 25 | $-1.66 | $0.10 | ||
| Q1 25 | $0.14 | $-0.10 | ||
| Q4 24 | $-8.64 | $0.17 | ||
| Q3 24 | $0.09 | $0.20 | ||
| Q2 24 | $0.04 | $0.20 | ||
| Q1 24 | $-0.02 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $28.0M |
| Total DebtLower is stronger | $90.3M | $178.0M |
| Stockholders' EquityBook value | $778.2M | $235.1M |
| Total Assets | $1.1B | $578.8M |
| Debt / EquityLower = less leverage | 0.12× | 0.76× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $28.0M | ||
| Q3 25 | $70.5M | $27.8M | ||
| Q2 25 | $90.3M | $20.0M | ||
| Q1 25 | $97.0M | $18.5M | ||
| Q4 24 | $107.7M | $18.3M | ||
| Q3 24 | $89.0M | $20.4M | ||
| Q2 24 | $92.2M | $17.2M | ||
| Q1 24 | $75.8M | $16.9M |
| Q4 25 | $90.3M | $178.0M | ||
| Q3 25 | $93.4M | $202.3M | ||
| Q2 25 | $95.7M | $189.4M | ||
| Q1 25 | $98.0M | $171.9M | ||
| Q4 24 | $125.3M | $169.6M | ||
| Q3 24 | $152.6M | $189.7M | ||
| Q2 24 | $164.9M | $199.7M | ||
| Q1 24 | $167.2M | $198.4M |
| Q4 25 | $778.2M | $235.1M | ||
| Q3 25 | $778.0M | $227.4M | ||
| Q2 25 | $776.3M | $215.8M | ||
| Q1 25 | $839.4M | $198.7M | ||
| Q4 24 | $828.5M | $198.6M | ||
| Q3 24 | $1.2B | $205.2M | ||
| Q2 24 | $1.2B | $193.2M | ||
| Q1 24 | $1.2B | $187.1M |
| Q4 25 | $1.1B | $578.8M | ||
| Q3 25 | $1.1B | $596.3M | ||
| Q2 25 | $1.0B | $571.0M | ||
| Q1 25 | $1.1B | $526.8M | ||
| Q4 24 | $1.2B | $523.0M | ||
| Q3 24 | $1.7B | $551.7M | ||
| Q2 24 | $1.7B | $548.1M | ||
| Q1 24 | $1.7B | $542.1M |
| Q4 25 | 0.12× | 0.76× | ||
| Q3 25 | 0.12× | 0.89× | ||
| Q2 25 | 0.12× | 0.88× | ||
| Q1 25 | 0.12× | 0.87× | ||
| Q4 24 | 0.15× | 0.85× | ||
| Q3 24 | 0.12× | 0.92× | ||
| Q2 24 | 0.13× | 1.03× | ||
| Q1 24 | 0.14× | 1.06× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $32.1M |
| Free Cash FlowOCF − Capex | $21.3M | $26.0M |
| FCF MarginFCF / Revenue | 11.8% | 14.3% |
| Capex IntensityCapex / Revenue | 3.8% | 3.4% |
| Cash ConversionOCF / Net Profit | — | 8.55× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $8.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $32.1M | ||
| Q3 25 | $14.0M | $4.5M | ||
| Q2 25 | $6.8M | $-9.3M | ||
| Q1 25 | $25.7M | $5.6M | ||
| Q4 24 | $57.9M | $25.7M | ||
| Q3 24 | $23.0M | $19.4M | ||
| Q2 24 | $27.8M | $4.5M | ||
| Q1 24 | $-8.0M | $604.0K |
| Q4 25 | $21.3M | $26.0M | ||
| Q3 25 | $7.0M | $-4.1M | ||
| Q2 25 | $-4.2M | $-14.7M | ||
| Q1 25 | $19.0M | $1.1M | ||
| Q4 24 | $53.1M | $22.1M | ||
| Q3 24 | $20.0M | $14.6M | ||
| Q2 24 | $21.9M | $-284.0K | ||
| Q1 24 | $-12.1M | $-4.2M |
| Q4 25 | 11.8% | 14.3% | ||
| Q3 25 | 3.9% | -2.1% | ||
| Q2 25 | -2.4% | -7.9% | ||
| Q1 25 | 11.3% | 0.7% | ||
| Q4 24 | 29.6% | 12.8% | ||
| Q3 24 | 11.7% | 8.0% | ||
| Q2 24 | 12.8% | -0.1% | ||
| Q1 24 | -7.3% | -2.3% |
| Q4 25 | 3.8% | 3.4% | ||
| Q3 25 | 3.9% | 4.4% | ||
| Q2 25 | 6.3% | 2.9% | ||
| Q1 25 | 4.0% | 2.8% | ||
| Q4 24 | 2.7% | 2.1% | ||
| Q3 24 | 1.8% | 2.6% | ||
| Q2 24 | 3.4% | 2.5% | ||
| Q1 24 | 2.5% | 2.6% |
| Q4 25 | — | 8.55× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | -3.07× | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | 4.96× | ||
| Q3 24 | 5.35× | 3.02× | ||
| Q2 24 | 15.44× | 0.71× | ||
| Q1 24 | — | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
MG
Segment breakdown not available.
